Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 9:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 916 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervix Neoplasm Clear all
Completed Not applicable Interventional

Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs

NCT03726151
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
11 Years to 17 Years
Enrollment
17,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
7
States / cities
Canoga Park, California • Pacoima, California • San Fernando, California + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Feasibility of the Management of Severe Cervical Dysplasia in a Single Visit

NCT00237562
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
Large loop electrosurgical excision
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 5, 2006 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 3 Interventional Results available

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866
View directory record Official record
Conditions
Locally Advanced Cervical Cancer
Interventions
Durvalumab, Cisplatin, Carboplatin, external beam radiation therapy (EBRT) + brachytherapy
Biological · Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 3, 2026, 9:10 PM EDT
Not yet recruiting Phase 2 Interventional

Topical Curcumin for HPV Related Cervical Disease

NCT04266275
View directory record Official record
Conditions
Neoplasm Cervix
Interventions
Curcumin C3 Complex, Placebo
Drug
Lead sponsor
Lisa Flowers
Other
Eligibility
21 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 3, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Results available

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

NCT00262821
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Interventions
cisplatin, tirapazamine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
273
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 3, 2026, 9:10 PM EDT
Not listed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

NCT00292955
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Cetuximab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors

NCT00066651
View directory record Official record
Conditions
Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
Interventions
SS1(dsFv)-PE38 immunotoxin
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Bethesda, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Intervention Promoting HPV Vaccination in Safety-net Clinics

NCT01729429
View directory record Official record
Conditions
Human Papilloma Virus-Related Cervical Carcinoma
Interventions
HPV brochure, recall, reminders, General Adolescent Vaccine Brochure
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years to 18 Years · Female only
Enrollment
831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 3, 2026, 9:10 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers

NCT00178802
View directory record Official record
Conditions
Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
Interventions
thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 3, 2026, 9:10 PM EDT
Terminated Phase 1 Interventional

FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer

NCT02317302
View directory record Official record
Conditions
Cervical Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasms
Interventions
FDG-PET/MR, FDG-PET/CT
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 2 Interventional

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

NCT00178269
View directory record Official record
Conditions
Cervix Neoplasm
Interventions
docetaxel, Radiation Therapy
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2009 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3

NCT02651883
View directory record Official record
Conditions
Cervical Cancer, Uterine Cervical Neoplasms, Human Papillomavirus
Interventions
Screening invitation (with education), Self-collection for HPV testing
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
25 Years to 64 Years · Female only
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2022 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

NCT04504669
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
Interventions
AZD8701, Durvalumab
Drug · Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 101 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
6
States / cities
Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 3, 2026, 9:10 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Review of Cervical Cancer Screening Practices in Women Age >65

NCT06431724
View directory record Official record
Conditions
Cervical Cancer
Interventions
Patient Survey, Provider Survey
Other
Lead sponsor
Sarasota Memorial Health Care System
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 3, 2026, 9:10 PM EDT
Terminated Phase 1 Interventional

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

NCT04458259
View directory record Official record
Conditions
Neoplasm Metastasis
Interventions
PF-07265807, Sasanlimab, Axitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
25
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 3, 2026, 9:10 PM EDT
Completed No phase listed Observational

chemQbiosciences:Manual Liquid Based Cytology

NCT01837303
View directory record Official record
Conditions
Cervical Dysplasia, Cervical Cancer
Interventions
Pap smear
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 3, 2026, 9:10 PM EDT
Recruiting Not applicable Interventional

Personalized Risk-based Follow-up of Cervical Cancer Screening in Practice, RCT

NCT06872346
View directory record Official record
Conditions
Cervical Cancer Screening
Interventions
Visit-based IT reminders to patients and practitioners, Population outreach
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 3, 2026, 9:10 PM EDT
Terminated Phase 4 Interventional Results available

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

NCT03423082
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer
Interventions
18F fluciclovine, 18F fluciclovine PET
Drug · Device
Lead sponsor
Nghi Nguyen
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients

NCT04374760
View directory record Official record
Conditions
Cervical Cancer
Interventions
SMS-intervention
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Dansville, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 3, 2026, 9:10 PM EDT
Terminated Phase 3 Interventional Results available

Spectroscopy Versus Standard Care in Cervical Cancer Patients

NCT00529464
View directory record Official record
Conditions
Cervical Cancer
Interventions
Fluorescence Spectroscopy, Colposcopy, LEEP Procedure
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 3, 2026, 9:10 PM EDT
Completed No phase listed Observational

Cervix Image Sharing Protocol (CISP)

NCT03179306
View directory record Official record
Conditions
Cervical Cancer, Cervical Abnormalities
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
27,084 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Oct 3, 2026, 9:10 PM EDT
Completed Phase 1 Interventional

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Interventions
XB002, Nivolumab, Bevacizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 3, 2026, 9:10 PM EDT